OncoPrecision: Funding, Investors & Team (Sep 2026)
We're developing technologies to replicate cancer patients' disease ex-vivo to rapidly and accurately test a broad range of treatments simultaneously to help oncologists provide the most suitable treatment for each patient and pharmaceutical companies develop transformational therapies.
OncoPrecision has raised $3.6M across 2 funding rounds on record, the most recent a Seed of $3.3M announced in Aug 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
OncoPrecision Company Profile and Key Stats
Latest funding round on record: Aug 2022.
OncoPrecision Funding Rounds
OncoPrecision raised $300k in a Pre-Seed announced in Feb 2021.
1.5 years later, a Seed of $3.3M was announced in Aug 2022.
OncoPrecision Founders and Leadership Team
Contact details for the OncoPrecision team: 1 of 1 has an email address on file.
Start 14-day free trial →OncoPrecision Funding Compared to Other Biotechnology Startups
OncoPrecision's latest round of $3.3M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like OncoPrecision in Biotechnology and New York
Companies Similar to OncoPrecision
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
OncoPrecision Funding FAQs
What does OncoPrecision do?
We're developing technologies to replicate cancer patients' disease ex-vivo to rapidly and accurately test a broad range of treatments simultaneously to help oncologists provide the most suitable treatment for each patient and pharmaceutical companies develop transformational therapies.
How much funding has OncoPrecision raised?
OncoPrecision has raised $3.6M across 2 rounds on record. The most recent is a Seed of $3.3M announced in Aug 2022.
When did OncoPrecision last raise funding?
OncoPrecision's most recent funding round on record is a Seed of $3.3M, announced in Aug 2022.
Who is the CEO of OncoPrecision?
Tarek Ali Zaki is listed as CEO at OncoPrecision.
Where is OncoPrecision headquartered?
OncoPrecision is based in New York, United States.
How many employees does OncoPrecision have?
OncoPrecision is in the 11-50 employee band.
How does OncoPrecision's funding compare to other Biotechnology startups?
OncoPrecision's latest round of $3.3M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's OncoPrecision Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for OncoPrecision is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.